NasdaqGS:BIDU
NasdaqGS:BIDUInteractive Media and Services

A Look at Baidu’s (NasdaqGS:BIDU) Valuation Following Abu Dhabi Driverless Robotaxi Milestone

Baidu (NasdaqGS:BIDU) caught attention after Apollo Go, its autonomous ride-hailing arm, and AutoGo secured one of Abu Dhabi's first fully driverless commercial permits. The partners also agreed to expand their robotaxi fleet to hundreds of vehicles by 2026. See our latest analysis for Baidu. The Abu Dhabi expansion news came just as Baidu’s stock notched a 45% gain in the past 90 days and a year-to-date share price return of nearly 60%. This signals renewed momentum after a rocky few years...
NasdaqGS:CLBT
NasdaqGS:CLBTSoftware

Could Cellebrite (CLBT) Strengthen Its Regulatory Edge With New Legal Leadership Amid AI Transitions?

Cellebrite DI Ltd. recently appointed Holly Windham as General Counsel and Chief Compliance Officer, highlighting her background in legal leadership, compliance, and technology sector expertise, and succeeding Ayala Berler Shapira in this role. This leadership change comes as Greenhaven Road Capital spotlighted Cellebrite as a top holding, pointing to subscription revenue growth and ongoing sector challenges related to AI adoption in software. We’ll explore how Ms. Windham’s compliance and...
NYSE:RKT
NYSE:RKTDiversified Financial

Why Rocket Companies (RKT) Is Up 6.5% After Redfin and Mr. Cooper Integration Momentum

In the past quarter, Rocket Companies, Inc. reported third-quarter revenue of US$1.61 billion and a net loss of US$123.85 million, reflecting major year-over-year increases in both revenue and losses. The company emphasized significant momentum from its integration of newly acquired Redfin and the completed Mr. Cooper transaction, which have rapidly expanded its capabilities across the homeownership platform. We'll explore how the successful integration of Mr. Cooper could influence Rocket...
NYSE:IQV
NYSE:IQVLife Sciences

IQVIA (IQV): Assessing Valuation After Nobel Laureate Dr. Kaelin Joins Board

IQVIA Holdings has announced that Dr. William G. Kaelin Jr., Nobel Prize-winning physician-scientist, is joining its board of directors. Investors may view this move as a way to strengthen the company’s scientific leadership and strategic direction. See our latest analysis for IQVIA Holdings. IQVIA Holdings' 14.9% share price gain over the past three months hints at growing investor enthusiasm, likely sparked by fresh scientific leadership and a renewed sense of direction. However, the 1-year...
NasdaqGS:RIVN
NasdaqGS:RIVNAuto

US Stock Market Today: S&P 500 Futures Rise as December Rate Cut Odds Climb

The Morning Bull - US Market Morning Update Wednesday, Nov, 12 2025 US stock futures are pointing higher this morning, as investors focus on mixed signals from the labor market and the growing chance of a December interest rate cut. The main factor fueling optimism is a 68% probability of rates being cut, which has lifted key futures like the S&P 500 by about 0.4% before the bell. However, job data shows private employers are slowing their hiring, with job cuts averaging over 11,000 a week,...
NasdaqCM:RKLB
NasdaqCM:RKLBAerospace & Defense

How the 20% Drop Shapes Rocket Lab’s 2025 Valuation Outlook

Wondering if Rocket Lab stock is a bargain or already priced for perfection? Let’s dig into what the numbers and recent events are telling investors right now. Rocket Lab has soared 105.3% year-to-date and an incredible 249.5% over the past year, though it's pulled back sharply, dropping 20.3% in just the last month. This rollercoaster ride has been shaped by headlines ranging from major contract wins with government agencies to notable technological achievements, such as their reusable...
NYSE:PFS
NYSE:PFSBanks

A Look at Provident Financial Services's Valuation Following Strong Q3 Growth and Lower Loan Charge-Offs

Provident Financial Services (PFS) just delivered its third quarter update, revealing strong gains in both net interest income and net income. Net loan charge-offs declined compared to last year, which could sway investor outlook. See our latest analysis for Provident Financial Services. Despite a strong earnings quarter and a fresh dividend announcement, Provident Financial Services hasn’t translated its improved fundamentals into market momentum just yet. The share price edged up only 1.4%...
NasdaqGS:NBIX
NasdaqGS:NBIXBiotechs

Neurocrine Biosciences (NBIX): Assessing Valuation After Lead Depression Drug Misses Phase 2 Study Goal

Neurocrine Biosciences (NBIX) just shared results from a Phase 2 study of its experimental treatment for major depressive disorder. The results revealed the compound failed to meet its main efficacy goal compared to placebo. See our latest analysis for Neurocrine Biosciences. Shares of Neurocrine Biosciences have shown resilience lately, with a 7.8% one-month share price return and a 12% gain over the past 90 days, despite news that its lead depression compound failed a key Phase 2 trial...